Bicara TherapeuticsBCAX -2.59%12 EV-to-EBITDA is -7.83 as of Jul. 11, 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 392 Biotechnology companies, Bicara Therapeutics ranks worse than 255101.79% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bicara Therapeutics's enterprise value is $1,361.18 Mil.
Bicara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-173.93 Mil. Therefore, Bicara Therapeutics's EV-to-EBITDA for today is -7.83.
The historical rank and industry rank for Bicara Therapeutics's EV-to-EBITDA or its related term are showing as below:
BCAX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -8.12 Med: 0 Max: 0
Current: -7.83
BCAX's EV-to-EBITDA is ranked worse than 100% of 392
companies
in the Biotechnology industry
Industry Median: 12.935
vs BCAX: -7.83
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bicara Therapeutics's PE Ratio (TTM) for today is calculated as:
Bicara Therapeutics's share price for today is $28.88.
Bicara Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bicara Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bicara Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicara Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bicara Therapeutics's EV-to-EBITDA falls into.
Bicara Therapeutics's current Enterprise Value is $1,361.18 Mil.
Bicara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-173.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bicara Therapeutics (BCAX) has a EV-to-EBITDA of -7.83 as of Jul. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bicara Therapeutics. According to the industry distribution chart, Bicara Therapeutics ranks #999999 out of 392 companies in the Biotechnology industry.
Is Bicara Therapeutics' EV-to-EBITDA too high?
Bicara Therapeutics' current EV-to-EBITDA is -7.83. Based on the distribution chart, Bicara Therapeutics ranks #999999 out of 392 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' EV-to-EBITDA compare to ZYME and SRPT?
According to the Biotechnology industry distribution chart, Bicara Therapeutics ranks #999999 out of 392 companies for EV-to-EBITDA. This places Bicara Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 12.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.94, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bicara Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicara Therapeutics's current EV-to-EBITDA is -7.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current EV-to-EBITDA of -7.83. The current EV-to-EBITDA is -7.83. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current EV-to-EBITDA is -7.83 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score
Get the complete analysis for BCAX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCAX has been successfully added to your 
